Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Melnikova, Vladislava
Vibat, Cecile Rose T.
Ning, Van
Agafitei, Raluca Dana
Hanna, Diana L.
Hancock, Saege
Erlander, Mark G.
Lenz, Heinz-Josef
Barzi, Afsaneh
机构：
[1] Trovagene Inc, San Diego, CA USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Univ Southern Calif, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15011
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
  • [42] Capetabine plus irinotecan (CAPIRI) as first line treatment for patients with metastatic colorectal cancer(MCRC)
    Laudani, A.
    Alu, M.
    Leonardi, V
    Savio, G.
    Pepe, A.
    Palmisano, V
    Targaglia, L.
    Porretto, C.
    Manuguerra, G.
    Calabria, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : VII41 - VII41
  • [43] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [44] New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
    Prenen, Hans
    Tejpar, Sabine
    Van Cutsem, Eric
    CLINICAL CANCER RESEARCH, 2010, 16 (11) : 2921 - 2926
  • [45] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Ciardiello, Fortunato
    Tejpar, Sabine
    Papamichael, Demetris
    TARGETED ONCOLOGY, 2009, 4 (04) : 311 - 322
  • [46] TREATMENT PATTERNS AND OUTCOMES IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A COMMUNITY ONCOLOGY SETTING
    Cartwright, T. H.
    Pan, I
    Wen, L.
    Wadlow, R. C.
    Rembert, D.
    Seal, B.
    VALUE IN HEALTH, 2014, 17 (03) : A69 - A70
  • [47] Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC).
    Kidd, Michael Todd
    Wilcox, Ryan Eldredge
    Rogers, Jane
    Eng, Cathy
    Saadat, Siamak
    Lenz, Heinz-Josef
    Hubbard, Joleen Marie
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB
    Van Cutsem, Eric
    Lang, Istvan
    D'Haens, Geerts
    Moiseyenko, Vladimir
    Zaluski, Jerzy
    Folprecht, Gunnar
    Tejpar, Sabine
    Nippgen, Johannes
    Stroh, Christopher
    Rougier, Philippe
    ANNALS OF ONCOLOGY, 2008, 19 : 4 - 4
  • [49] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Fortunato Ciardiello
    Sabine Tejpar
    Demetris Papamichael
    Targeted Oncology, 2009, 4 : 311 - 322
  • [50] Raltitrexed (Tomudex®) treatment for elderly patients with metastatic colorectal cancer (MCRC):: Preliminary toxicity report
    Facchini, T
    Genet, D
    Berdah, JF
    Nouyrigat, P
    Dutin, JP
    Laplaige, P
    Smith, M
    Fandi, A
    ANNALS OF ONCOLOGY, 1998, 9 : 41 - 41
12345